OCS logo

Oculis Holding ICSE:OCS Stock Report

Last Price

Kr1.65k

Market Cap

Kr68.5b

7D

-0.6%

1Y

n/a

Updated

14 Jun, 2024

Data

Company Financials +

Oculis Holding AG Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Oculis Holding
Historical stock prices
Current Share PriceUS$1,650.00
52 Week HighUS$1,850.00
52 Week LowUS$1,610.00
Beta0.082
1 Month Change-2.94%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-2.37%

Recent News & Updates

Recent updates

Shareholder Returns

OCSIS PharmaceuticalsIS Market
7D-0.6%0%0%
1Yn/a0%0%

Return vs Industry: Insufficient data to determine how OCS performed against the IS Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how OCS performed against the IS Market.

Price Volatility

Is OCS's price volatile compared to industry and market?
OCS volatility
OCS Average Weekly Movement3.8%
Pharmaceuticals Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in IS Market0%
10% least volatile stocks in IS Market0%

Stable Share Price: OCS has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine OCS's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a36Riad Sherifoculis.com

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

Oculis Holding AG Fundamentals Summary

How do Oculis Holding's earnings and revenue compare to its market cap?
OCS fundamental statistics
Market capKr68.49b
Earnings (TTM)-Kr9.17b
Revenue (TTM)Kr136.36m

502.3x

P/S Ratio

-7.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OCS income statement (TTM)
RevenueCHF876.00k
Cost of RevenueCHF33.96m
Gross Profit-CHF33.08m
Other ExpensesCHF25.80m
Earnings-CHF58.88m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.41
Gross Margin-3,776.14%
Net Profit Margin-6,721.46%
Debt/Equity Ratio0%

How did OCS perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.